Substituted xanthones as antimycobacterial agents, Part 2: Antimycobacterial activity

Area of Science:

• Medicinal Chemistry
• Microbiology
• Pharmacology

Background:

• Mycobacterial infections, including tuberculosis, remain a significant global health challenge.
• There is a continuous need for novel therapeutic agents with improved efficacy and safety profiles.
• Xanthone derivatives are a class of compounds with diverse biological activities, warranting investigation for antimycobacterial properties.

Purpose of the Study:

• To evaluate the antimycobacterial activity of a series of substituted xanthone compounds.
• To identify potent xanthone derivatives against various mycobacterial strains, including Mycobacterium tuberculosis.
• To characterize the mechanism of action for the most active compounds through bacterial growth kinetics.

Main Methods:

• Minimum Inhibitory Concentrations (MIC) were determined for substituted xanthones against Mycobacterium tuberculosis, M. avium, M. lufu, and M. smegmatis.
• Bacterial growth kinetics assays were performed for highly active compounds to elucidate their antimycobacterial effects.
• Compounds were semiquantitatively classified into three activity groups for future Quantitative Structure-Activity Relationship (QSAR) studies.

Main Results:

• 1-methyl-2,4,7-trinitroxanthone (8a) exhibited the highest antimycobacterial activity, with a MIC of 3 µg/mL against Mycobacterium tuberculosis.
• The observed activity of compound 8a is comparable to established anti-tuberculosis drugs.
• Many other tested xanthone derivatives displayed limited activity or poor solubility, preventing MIC determination.

Conclusions:

• Substituted xanthones, particularly 1-methyl-2,4,7-trinitroxanthone, show promising antimycobacterial potential.
• Compound 8a represents a lead candidate for further development in tuberculosis treatment strategies.
• The study lays the groundwork for QSAR investigations to optimize xanthone-based antimycobacterial agents.